Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a report issued on Tuesday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 1.0 %

NASDAQ:SUPN opened at $32.49 on Tuesday. Supernus Pharmaceuticals has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 30.36 and a beta of 0.84. The stock’s 50 day moving average price is $34.68 and its two-hundred day moving average price is $35.03.

Insiders Place Their Bets

In other news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last three months. Insiders own 9.30% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SUPN. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock valued at $222,411,000 after buying an additional 22,852 shares in the last quarter. Geode Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock valued at $54,633,000 after acquiring an additional 28,517 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock valued at $41,248,000 after acquiring an additional 95,777 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after purchasing an additional 40,968 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company’s stock worth $25,933,000 after purchasing an additional 110,867 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.